RECURRENT CERVICAL CANCER
Clinical trials for RECURRENT CERVICAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CERVICAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT CERVICAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets advanced gynecologic cancers in early trial
Disease control Recruiting nowThis study tests a combination of two drugs, becotatug vedotin and zimberelimab, in 30 people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have already tried at l…
Matched conditions: RECURRENT CERVICAL CANCER
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy offers hope for advanced cervical cancer patients
Disease control Recruiting nowThis study tests a combination of immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without bevacizumab, in 120 adults with metastatic, persistent, or recurrent cervical cancer. The goal is to see if this approach helps patients live longer and controls the d…
Matched conditions: RECURRENT CERVICAL CANCER
Phase: PHASE2, PHASE3 • Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for advanced cervical cancer: experimental drug SHR-A2102 enters phase 3 trial
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called SHR-A2102 against standard chemotherapy in 398 people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and PD-(L)1 inhibitors. The main goal is to see if SHR-A2102 helps people live longer.…
Matched conditions: RECURRENT CERVICAL CANCER
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New registry aims to learn from Real-World retreatment of gynecologic cancers
Knowledge-focused Recruiting nowThis observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …
Matched conditions: RECURRENT CERVICAL CANCER
Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC